Hims Shares Plunge After FDA Threatens Action on 'Illegal Copycat Drugs ...

FDA to restrict GLP-1 ingredients used in non‑approved compounded drugs

The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs

Hims & Hers stock closes at one-year low amid battle over compounded Wegovy pill

Hims & Hers also said it’s selling a cancer-detection test that’s featured in its Super Bowl ad, which plays like a commentary on the wealthy’s access to better healthcare. Article Attribution | Read More at Article Source The post Hims & Hers stock closes at one-year low amid battle over compounded Wegovy pill appeared first on RocketNews.

FDA Chief Signals Crackdown on Companies Marketing Illegal Copycat Drugs

The U.S. Food and Drug Administration (FDA) will take action against companies that mass-market illegal copycat versions of FDA-approved drugs, FDA commissioner Marty Makary said on Feb. 5. Makary warned that some companies are marketing drugs as comparable to FDA-approved products without safety verification. “The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs,” the FDA commissioner said on X. He did not specify w…

FDA Cracks Down on Copycat Drug Market Amid Hims Controversy

FDA Cracks Down on Copycat Drug Market Amid Hims Controversy The U.S. Food and Drug Administration (FDA) is poised to clamp down on companies marketing unapproved drugs that mimic FDA-sanctioned products. Commissioner Marty Makary highlighted this concern following Hims and Hers Health's launch of a $49 compounded version of Novo Nordisk's new weight-loss pill, Wegovy.The announcement caused a 10% drop in Hims' stock during after-hours trading. …

Hims shares plunge after FDA threatens action on 'illegal copycat drugs ...